Company intelligence / Profile preview

SGX Group

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

SGX Pharmaceuticals was a biotechnology company specializing in structure-guided drug discovery and development, primarily focused on oncology. The company utilized its proprietary FAST (Fragment-based Analysis and Structural Targets) platform to identify and optimize small molecule drug candidates by leveraging X-ray crystallography and structural biology. Its lead program, SGX523, was a highly selective MET inhibitor designed to treat various solid tumors. SGX Pharmaceuticals was acquired by Eli Lilly in 2008 for approximately $64 million, integrating its structural biology expertise and pipeline into Lilly's oncology portfolio.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Eli LillyNovartis

Beyond the preview

Go deeper on SGX Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGX Group.

Explore the full profile